Emerging Drugs and Targets for Alzheimer's Disease (eBook, PDF)

Volume 2: Neuronal Plasticity
Redaktion: Martinez, Ana

• Format: PDF

Produktbeschreibung

Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer's disease.

Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts, these volumes are an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, D ausgeliefert werden.

Produktdetails

• Verlag: RSC
• Seitenzahl: 326
• Erscheinungstermin: 7. Mai 2010
• Englisch
• ISBN-13: 9781849731072
• Artikelnr.: 44762529

Autorenporträt

Ana Martinez obtained her PhD in Organic Chemistry from the Complutense University of Madrid before becoming a researcher at the Medicinal Chemistry Institute of the Spanish National Council for Research (CSIC). Since 1995, her interests have focused on neurodegenerative disorders and she has led numerous research projects on the medicinal chemistry and rational drug design with the aim of finding new treatments for Alzheimer's disease. In February 2002, she joined NeuroPharma (now NOSCIRA) as R&D Director where she led projects from the discovery of potential new therapies to the final proof of concept in animal models. In February 2008, she returned to her academic position at the Medicinal Chemistry Institute (CSIC) leading several projects on neurodegenerative disease therapies and acting as an external scientific advisor to a number of pharmaceutical companies. Her main areas of research currently involve GSK-3 inhibitors and dual binding site acetylcholinesterase inhibitors. She has authored over a hundred and fifty scientific publications and has more than twenty active patents in the field.

Inhaltsangabe

Neuronal Plasticity as target
Chapter 15: Regeneration of Degenerated Brain: A Promising Therapeutic Target
Chapter 16: Promoting synaptic resilience in AD patients through PDE inhibition
Chapter 17: A new generation of non invasive NGF-based therapies for Alzheimer's disease
Chapter 18: Possible clinical applications of stem cell strategies in AD therapies
Neuronal protection as target
Chapter 19: Targeting Oxidative Mechanisms in Alzheimer Disease
Chapter 20: Davunetide (NAP) Pharmacology: Neuroprotection and tau
Chapter 21: Targeting NF- B inflammatory and pro-survival signaling in AD
Chapter 22: PPAR in Alzheimer`s disease
Miscellaneous targets and strategies
Chapter 23: Serotonin 5-HT4 receptors as pharmacological targets for the treatment of Alzheimer¿s disease
Chapter 24: Liver X Receptors as potential therapeutic target for AD
Chapter 25: Discovery of memoquin, a multi-target-directed ligand for the treatment of Alzheimer's disease
Chapter 26: RNA interference of genes related to AD
Chapter 27: Medicinal plants, phytochemicals and Alzheimer's Disease